About China R&D Center

About Pfizer

Pfizer, a leader among global biopharmaceutical companies, has been established in China since the 1980s. Pfizer’s presence and activities in China started with commercial offices, and has evolved to include manufacturing (e.g., several plants commenced operations in China during the 1980s and 1990s, including Dalian and Suzhou), as well as R&D – with the establishment of Pfizer’s China R&D Center (CRDC) in Shanghai in 2005. The last decade has seen a significant expansion of Pfizer’s R&D footprint, facilities and capabilities, notably with the launch of CRDC’s sister satellite R&D site in Wuhan in 2010. Currently the market leader among multinational biopharmaceutical companies in China, Pfizer has approximately 1,500 R&D colleagues working in China, with a concentration in three key sites affiliated to CRDC – namely Shanghai, Wuhan and Beijing.

CRDC supports Pfizer’s global biological and chemical pharmaceutical R&D programs across our clinical development pipeline, and serves as an important hub of Pfizer global and Asia-Pacific R&D activities. As such, CRDC is an integral part of Pfizer’s global R&D site network, providing support across many R&D disciplines, including clinical drug development, medical, regulatory and safety.

CRDC has continually contributed to the biopharmaceutical R&D environment in China to promote the R&D of innovative medicines in China. We have partnered on many collaborative efforts with leading academic institutions and universities, including Peking University, Tsinghua University, Fudan University, and the China Academy of Sciences. CRDC has sponsored, chaired and presented at many external workshops, industry and academic conferences in China, including multiple workshops for the Center of Drug Evaluation (CDE) and Center of Drug Re-Evaluation (CDR) of the CFDA, on clinical pharmacology and pharmacometrics, pharmacovigilance and safety reporting, data mining, clinical data management, among other areas.

CRDC’s aspiration is to help accelerate China’s transition to an innovative economy by catalyzing the upgrade of local R&D capabilities, systems, technologies/IP, and culture, to address unmet medical needs, and create a world-class biopharmaceutical R&D ecosystem for China, as part of the global R&D community. We certainly will continue to innovate and bring important new medicines from Pfizer’s pipeline to patients in China.

Text SizeAAA